Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
110.80 +1.82 (+1.67%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 110.80 unch (unch) 16:27 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
107.66
Day High
111.17
Open 108.52
Previous Close 108.98 108.98
Volume 896,300 896,300
Avg Vol 1,363,120 1,363,120
Stochastic %K 58.60% 58.60%
Weighted Alpha -4.07 -4.07
5-Day Change +8.02 (+7.80%) +8.02 (+7.80%)
52-Week Range 95.49 - 148.06 95.49 - 148.06
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,618,573
  • Shares Outstanding, K 60,732
  • Annual Sales, $ 4,069 M
  • Annual Income, $ 560,120 K
  • EBIT $ 1,344 M
  • EBITDA $ 2,004 M
  • 60-Month Beta 0.42
  • Price/Sales 1.56
  • Price/Cash Flow 3.43
  • Price/Book 1.54

Options Overview Details

View History
  • Implied Volatility 45.07% ( +0.62%)
  • Historical Volatility 53.59%
  • IV Percentile 91%
  • IV Rank 59.28%
  • IV High 62.45% on 04/10/25
  • IV Low 19.77% on 01/21/25
  • Put/Call Vol Ratio 0.59
  • Today's Volume 46
  • Volume Avg (30-Day) 756
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 8,156
  • Open Int (30-Day) 9,876

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 3.96
  • Number of Estimates 8
  • High Estimate 5.31
  • Low Estimate 2.85
  • Prior Year 1.98
  • Growth Rate Est. (year over year) +100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
95.49 +16.03%
on 04/09/25
Period Open: 135.25
134.90 -17.87%
on 03/26/25
-24.45 (-18.08%)
since 03/25/25
3-Month
95.49 +16.03%
on 04/09/25
Period Open: 122.04
148.06 -25.16%
on 02/26/25
-11.24 (-9.21%)
since 01/24/25
52-Week
95.49 +16.03%
on 04/09/25
Period Open: 107.43
148.06 -25.16%
on 02/26/25
+3.37 (+3.14%)
since 04/25/24

Most Recent Stories

More News
3 Small-Cap Stocks in the Doghouse

3 Small-Cap Stocks in the Doghouse

MHK : 106.87 (-2.04%)
JAZZ : 110.80 (+1.67%)
FNKO : 4.30 (-0.23%)
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?

Jazz Pharmaceuticals JAZZ and Harmony Biosciences HRMY have emerged as notable players in the neuroscience space, especially in the sleep disorder segment.Jazz Pharmaceuticals markets multiple neuroscience...

JAZZ : 110.80 (+1.67%)
HRMY : 29.61 (+0.61%)
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025?

While JAZZ Pharmaceuticals JAZZ may not be a typical cannabis stock, it is the only company to market an FDA-approved drug that contains a purified drug substance derived from marijuana.The company entered...

JAZZ : 110.80 (+1.67%)
TLRY : 0.4871 (-1.06%)
CMRX : 8.54 (-0.12%)
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

JAZZ : 110.80 (+1.67%)
VTRS : 8.13 (+1.25%)
MRK : 82.74 (+3.63%)
ANIP : 69.82 (+0.26%)
BMY : 47.90 (-1.62%)
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag

Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational pipeline candidate FT819 for the treatment of active...

KRYS : 168.06 (-0.63%)
JAZZ : 110.80 (+1.67%)
ADMA : 21.86 (-2.10%)
FATE : 1.2800 (-5.19%)
Ironwood Shares Tank on Regulatory Update for Apraglutide

Shares of Ironwood Pharmaceuticals IRWD plunged 31.5% yesterday after it announced regulatory updates on the next-generation GLP-2 analog, apraglutide, which is being developed for treating short bowel...

KRYS : 168.06 (-0.63%)
IRWD : 0.8885 (+1.12%)
JAZZ : 110.80 (+1.67%)
ADMA : 21.86 (-2.10%)
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to protect...

KRYS : 168.06 (-0.63%)
JAZZ : 110.80 (+1.67%)
ADMA : 21.86 (-2.10%)
ARCT : 12.91 (+0.16%)
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Shares of TG Therapeutics, Inc. TGTX have rallied 29.5% in the past three months against the industry’s decline of 11.2%.The company’s sole marketed drug Briumvi (ublituximab-xiiy) was approved by...

TGTX : 41.33 (+2.56%)
KRYS : 168.06 (-0.63%)
DTIL : 5.33 (-3.09%)
JAZZ : 110.80 (+1.67%)
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?

Share price of JAZZ Pharmaceuticals JAZZ hit $102.82 on Tuesday, close to its 52-week low of $99.06.This decline is attributable to the significant downturn in the broader biotech/drug sector due to the...

JAZZ : 110.80 (+1.67%)
EBS : 5.49 (+2.23%)
CMRX : 8.54 (-0.12%)
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive daytime...

KRYS : 168.06 (-0.63%)
JAZZ : 110.80 (+1.67%)
DVAX : 10.82 (-0.73%)
AXSM : 106.27 (+0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients....

See More

Key Turning Points

3rd Resistance Point 115.60
2nd Resistance Point 113.39
1st Resistance Point 112.09
Last Price 110.80
1st Support Level 108.58
2nd Support Level 106.37
3rd Support Level 105.07

See More

52-Week High 148.06
Fibonacci 61.8% 127.98
Fibonacci 50% 121.77
Fibonacci 38.2% 115.57
Last Price 110.80
52-Week Low 95.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective